Bank of New York Mellon’s AIM ImmunoTech AIM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-253
Closed -$11.1K 4396
2023
Q4
$11.1K Hold
253
﹤0.01% 4265
2023
Q3
$11.5K Hold
253
﹤0.01% 4286
2023
Q2
$16.9K Hold
253
﹤0.01% 4306
2023
Q1
$10.9K Hold
253
﹤0.01% 4351
2022
Q4
$7.88K Hold
253
﹤0.01% 4433
2022
Q3
$15K Hold
253
﹤0.01% 4481
2022
Q2
$20K Sell
253
-23
-8% -$2.21K ﹤0.01% 4496
2022
Q1
$29K Hold
276
﹤0.01% 4596
2021
Q4
$25K Hold
276
﹤0.01% 4577
2021
Q3
$56K Buy
276
+23
+9% +$4.64K ﹤0.01% 4424
2021
Q2
$54K Hold
253
﹤0.01% 4320
2021
Q1
$57K Sell
253
-27
-10% -$6.1K ﹤0.01% 4241
2020
Q4
$50K Hold
280
﹤0.01% 4149
2020
Q3
$60K Buy
+280
New +$69.9K ﹤0.01% 4003
2018
Q2
Sell
-2
Closed -$4K 4455
2018
Q1
$4K Sell
2
-1
-33% -$2.09K ﹤0.01% 4308
2017
Q4
$5K Hold
3
﹤0.01% 4348
2017
Q3
$5K Sell
3
-3
-50% -$5.26K ﹤0.01% 4259
2017
Q2
$13K Buy
6
+3
+100% +$7.42K ﹤0.01% 4260
2017
Q1
$9K Buy
+3
New +$7.67K ﹤0.01% 4260
2016
Q3
Sell
-1
Closed -$8K 4429
2016
Q2
$8K Hold
1
﹤0.01% 4303
2016
Q1
$9K Hold
1
﹤0.01% 4201
2015
Q4
$5K Hold
1
﹤0.01% 4320
2015
Q3
$11K Hold
1
﹤0.01% 4350
2015
Q2
$14K Sell
1
-1
-50% -$12.4K ﹤0.01% 4247
2015
Q1
$30K Hold
2
﹤0.01% 4172
2014
Q4
$31K Buy
2
+1
+100% +$14.9K ﹤0.01% 4182
2014
Q3
$22K Hold
1
﹤0.01% 4201
2014
Q2
$21K Hold
1
﹤0.01% 4132
2014
Q1
$27K Buy
+1
New +$21.2K ﹤0.01% 4133
2013
Q3
Sell
-3
Closed -$30K 4298
2013
Q2
$30K Buy
+3
New +$35.8K ﹤0.01% 4083

Other funds holding AIM

Bank of New York Mellon's AIM Position: Q1 2024 in Review

Bank of New York Mellon sold out of AIM ImmunoTech (AIM) in Q1 2024, closing a stake of 253 shares — an estimated $11.1K sold.

Bank of New York Mellon first reported a position in AIM in Q2 2013 and held it in 30 quarters. The position peaked at $60K in Q3 2020. 28 funds tracked by Wall St. Rank hold AIM as of Q1 2024.

  • Bank of New York Mellon reported no remaining AIM ImmunoTech position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 253 AIM ImmunoTech shares in Q1 2024, an estimated $11.1K.
  • Bank of New York Mellon first reported a position in AIM ImmunoTech in Q2 2013 and held it in 30 quarters.
  • Bank of New York Mellon's AIM ImmunoTech position peaked at $60K in Q3 2020.
  • 28 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.